Bajaj Healthcare standalone net profit declines 36.68% in the December 2022 quarter

The pre-approval inspection has completed successfully with zero Form 483 observations of the manufacturing facility.

Bajaj Healthcare Completes USFDA Pre-Approval Inspection Of Vadodara Plant

The US Food and Drug Administration (USFDA) had conducted a pre-approval inspection of the facility from November 14, 2022, to November 17, 2022, Bajaj Healthcare Ltd (BHL) said in a regulatory filing.

Bajaj Healthcare successfully completes USFDA pre-approval inspection of Vadodara plant

Capacity ramp-up and new business opportunities should stand Bajaj Healthcare in good stead; any correction a scope to buy

Bajaj Healthcare: Weak Q1 not a dampener for long run

Bajaj Healthcare will now supply opium-derived alkaloids and active pharmaceutical ingredients to the Centre, who, in turn, will provide them to the pharmaceutical industry that will help them produce pain relievers, especially for cancer patients

In historic decision, India opens opium market to private players; Bajaj Healthcare first aboard

Bajaj Healthcare is the first private player to be awarded a tender to make alkaloids and APIs from opium gum

For the first time, Centre allows a private player to process opium

The company said that this will open up a new stream of revenue that has immense potential growth, as Bajaj Healthcare is currently the only player for government-allocated opiate processing on a long term basis.

Bajaj Healthcare first private company to foray into opiate processing biz for govt

Bajaj Healthcare said it has received two orders from the central government to produce active pharmaceutical ingredients (API) from poppy capsules and other derivatives on an annual basis

Bajaj Healthcare forays into highly-regulated opiate processing business

Bajaj Healthcare on Wednesday said it has forayed into the highly regulated opiate processing business. The company said it has received two orders from the central government to produce active pharmaceutical ingredients from poppy capsules and other derivatives on an annual basis.

Bajaj Healthcare forays into opiate processing business

Bajaj Healthcare advanced 3.55% to Rs 353.05 after the company said that it has received two letters of award for the manufacture of Alkaloids/APIs from Government of India.

Bajaj Healthcare gains on foraying into opiate processing biz

Bajaj Healthcare shares extended gains for the sixth straight session, rising to its highest since April

Bajaj Healthcare shares hit 3-mth high on foray into opiate processing business

Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of bulk drugs and pharmaceutical products. The Company's segments include manufacturing of Bulk Drugs, and Formulation and sale of medicines. 